William Blair & Co

William Blair & Co Downgrades CSCO To Market Perform

DTS On Course To Achieve Guidance In 2010

Weak Results By PEGA Attributed To Seasonality, Big-Deal Lumpiness, Tough Comparisons

DTS On Course To Achieve Guidance In 2010

Weak Results By PEGA Attributed To Seasonality, Big-Deal Lumpiness, Tough Comparisons

HRBN Continues To Be Optimistic Regarding Growth Opportunities

William Blair Increasing Estimates On Evercore (EVR)

HRBN Continues To Be Optimistic Regarding Growth Opportunities

William Blair Increasing Estimates On Evercore (EVR)

William Blair Likes Brookdale Senior Living Long Term

William Blair & Co. Reiterates Outperform on Genpact Limited (G)

William Blair & Co Recent News

Lack Of Recovery In Toxicology Prompts CVD To Reduce Guidance Further

William Blair Is Outperform On Vistaprint (VPRT)

BCR: Steady Second-Quarter Results, Outlook Improving

RAH: Fiscal Third-Quarter Earnings Roughly In Line With Preannouncement

CLU Maintains 2011 Earnings Guidance

HURN Amends Its Credit Facility

Recovery In FCN’s Strategic Communications Segment Stronger Than Expected

MSCI To Continue To Benefit From Globalization Of Cross-Border Platform

TRCR: Risk/Reward Ratio Favorable at Current Levels

Remodeled Fresh Stores Could Prove Important Catalyst For PTRY

MICROS Has Long Term Growth Opportunities

DreamWorks Animation Says 2Q Earnings to Decline

Vistaprint Retains ‘Outperform’ Rating (VPRT)

PRXL Introduces FY2011 Guidance In Line With Expectations

No Fundamental Or Structural Changes To BK’s Revenue Items

Exponent With More Attractive Valuation and High Conviction In Estimates

SPSC To Deliver Steady And Predictable Revenue Growth In Any Economic Environment

SGD Market To Grow In Midteens For Many Years; DVOX To Be The Primary Beneficiary

William Blair Upgrades State Street to Outperform (STT)

William Blair & Co. Reiterates Outperform Rating On Nalco Holding (NLC)

Decline in SLAB’s Mobile Handset FM Radios Business May Raise Concerns

ATHR Q1 Results May Easily Exceed Consensus

Phase III Development Of Drug Candidates By HALO To Boost Shareholder Value